Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|The Lancet Oncology|2011Cited by 4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C. Zhou, Changxuan You, Yi‐Long Wu et al.|Annals of Oncology|2015Cited by 467
TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influxJianpeng Chen, Rong Li, Yi Luan et al.|Cell Calcium|2010Cited by 135
CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patientsXiaotao Qian, Changxuan You, Zhiyong Yang et al.|Biomedicine & Pharmacotherapy|2015Cited by 126
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G. Chen, Changxuan You, J. Feng et al.|Annals of Oncology|2013Cited by 120